35 results
6-K
TAK
Takeda Pharmaceutical Co
2 Feb 24
Current report (foreign)
6:16am
arising from differences between the fixed prices and floating market prices of renewable energy in a virtual power purchase agreement and those … method. The key assumptions taken into account include forecasted renewable energy prices and the expected generation of the renewable energy
6-K
TAK
Takeda Pharmaceutical Co
1 Feb 24
Current report (foreign)
6:18am
in renewable energy or low carbon energy technology will enable us to reduce our greenhouse gas emissions; and other factors identified in Takeda’s most
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
1 Feb 24
Current report (foreign)
6:06am
energy conservation measures and future advancements in renewable energy or low carbon energy technology will enable us to reduce our greenhouse gas
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
30 Nov 23
Current report (foreign)
6:01am
conservation measures and future advancements in renewable energy or low carbon energy technology will enable us to reduce our greenhouse gas emissions
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
30 Oct 23
Current report (foreign)
6:02am
and future advancements in renewable energy or low carbon energy technology will enable us to reduce our greenhouse gas emissions; and other factors
6-K
mswxmmyf8u
30 Oct 23
Current report (foreign)
6:02am
6-K
EX-99.1
j0dc 0xb80w9z8pl98hb
26 Oct 23
Current report (foreign)
6:20am
6-K
34bofh9w5ysbj0wvagn
1 Aug 23
Current report (foreign)
6:10am
6-K
EX-99.1
jogvp89ov3qoszgfp4
27 Jul 23
Current report (foreign)
6:05am
6-K
EX-99.1
go4j6af7
6 Jul 23
Current report (foreign)
6:18am
6-K
EX-99.1
iic19uo5vyhp7ps pa6
23 Jun 23
Current report (foreign)
6:13am
6-K
EX-99.1
iveyo1959a
30 May 23
Current report (foreign)
6:19am
6-K
EX-99.1
ff056kcqtfh3qac2e
30 May 23
Current report (foreign)
6:14am
6-K
EX-99.1
x76p00hllccnvm9jevti
30 May 23
Current report (foreign)
6:11am
6-K
7bkfjw95ja
11 May 23
Current report (foreign)
6:07am
6-K
EX-99.1
nvtg1cnkobv qslz
11 May 23
Current report (foreign)
6:07am
6-K
s9donzn
13 Dec 22
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
7:00am
6-K
EX-99.1
v05 9823rb7v5
30 Nov 22
Current report (foreign)
6:28am
6-K
EX-99.1
v2lef85
27 Oct 22
Current report (foreign)
6:01am